28/05/2016 17:01:30 Cookie Policy +44 (0) 207 0700 961 Free Membership Login
Share Name Share Symbol Market Type Share ISIN Share Description
Kromek LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 30.50p 30.00p 31.00p 30.50p 30.50p 30.50p 11,791 07:38:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.1 -3.1 -2.0 - 46.42

Kromek (KMK) Latest News

More Kromek News
Kromek Takeover Rumours

Kromek (KMK) Share Charts

1 Year Kromek Chart

1 Year Kromek Chart

1 Month Kromek Chart

1 Month Kromek Chart

Intraday Kromek Chart

Intraday Kromek Chart

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
21/5/201607:46Kromek Group PLC550
19/5/201508:23Kromek Group (KMK) - Overvalued AIM mugging177

Add a New Thread

Kromek (KMK) Top Chat Posts

Kromek Daily Update: Kromek is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 30.50p.
Kromek has a 4 week average price of 32.68p and a 12 week average price of 32.39p.
The 1 year high share price is 49.50p while the 1 year low share price is currently 24.50p.
There are currently 152,211,082 shares in issue and the average daily traded volume is 62,230 shares. The market capitalisation of Kromek is £46,424,380.01.
bapodra_investments: I mean just look at the charts (above). It speaks volumes! There is more volume coming out of the charts than any buying or selling volume on this stock. Can anyone offer a seriously credible reason why the price action is not extremely positive on this stock? Can anyone offer a credible argument as to why this share price is not going upwards? Have a look at below which is from Proactive Investors today: ------------------------------------------------------------------------------------ Tech company investor Amphion Innovations Plc (LON:AMP) has drawn a further US$1.77mln from a loan facility secured against its holdings in Aim-listed Kromek (LON:KMK) and Motif Bio (LON: MTFB). Interest on the new funds will be a rate of 10% annually with repayments starting on 1 May and the final repayment due on 1 February. The facility was set up just under two years ago with a maximum draw down of US$10mln. The latest loan tranche will be used for working capital. It is secured on 7.77mln shares of Kromek and 14.9mln shares of Motif Bio. Richard Morgan, Amphion’s chief executive, said: "We continue to believe in the future upside potential of our holdings in both partner companies, Kromek and Motif Bio. “We are working on moving other programmes forward and this facility gives us access to additional working capital to progress the business' pipeline while these two partner companies develop further." Graham Lumsden, CEO of Motif Bio, said: "We welcome Amphion's continued commitment as a shareholder in Motif Bio." ------------------------------------------------------------------------------------ There is a big clue (above) for those savy investors who will realise what may be happening.
bapodra_investments: Can anyone explain why the dire share price performance over the past several months then? This must have all been priced in and therefore Kromek became overpriced! It always worries me when a share price does not react to positive news in a proportionate manner.
bapodra_investments: The DARPA deal has not made a difference to the share price. Now this concerns me. Bearing in mind that the stock market is a forward pricing mechanism looking say 6 months ahead then the fact the share price has not gone up tells me that revenue disability going forward is still a concern.
philjeans: From Equity Development today; Kromek is pioneering digital colour imaging for x- and gamma rays, using cadmium zinc telluride crystals. Key markets include: medical imaging, homeland security and nuclear detection. 'Dirty bombs'are a terrifying prospect that, if detonated, would wreak havoc in large cities like New York. Not only causing death and destruction at the blast zone, but also widespread contamination of public areas potentially to be cordoned off for weeks or months. This is why the US Department and Defense (DoD), via its DARPA division (Defense Advanced Research Projects Agency), has just placed two landmark orders with Kromek worth $6.75m in total, to help safeguard the nation from such bombs. DARPA's long term vision is to establish a comprehensive security blanket across large swathes of the country - meaning that this contract could ultimately be expanded to cover literally 100ks (if not millions) of government employees under one huge integrated network. Better still, the $500/unit price point is a global first, and we understand active discussions are already in motion with at least 2-3 other major customers to deploy this patented technology. When this is added to the $7m of deals secured in H1, and January's $1m bone mineral densitometry contract, we estimate that total FY16 order intake will be >$15m - representing a book:bill ratio of at least 125%, based on turnover of £8.4m. Demand also shows that the adoption of truly disruptive technologies is likely to occur even in the face of macro-economic headwinds. Our estimates suggest that Kromek should become EBITDA and cashflow positive on annualised revenues of circa £11.5m and £14.5m. No changes are made to our 42p/share price target.
bapodra_investments: Henderson raising their stake in Kromek to 5% yesterday is a encouraging sign. We need more fund management houses to take a stake in this company for the share price to really go up.
archway1: I think there may well be a bid for the company , it stands to reason that now is the time to do it before the new revenues and profits kick in. I think this is going to go the exact same way as Xchanging . Top dog joins the board of company with depressed share price at its bottom. Outlook very strong and company now on firm financial footing. I smell a bidding war!!
quepassa: Ranting. Me?? You just wrote 7 consecutive posts. Try and keep a grip. Or is it too difficult to put more than one thought in each post for you? What do I do? I finance companies like Kromek to help them build their plans. You soon get to understand which category they fit into. The good, the bad or the ugly. Without investors , this company is dead in the water in my view. This Company will need future equity investment and without it, it is unlikely to succeed. If you think the way that Kromek treats investors is clever, you are completely misguided. You see, that's it with Kromek. They tell you about all these wonderful contracts and are great at endless name-dropping but has that translated into profits? Don't get sucked in. Kromek displays one of the classic symptoms of university spin-outs. Academics don't necessarily translate well into the purely commercial world. After their shock Trading Statement in early 2014 which halved the share price so soon after their late 2013 IPO, this is what they came out with a short time later on 4th. April 2014 about a long-term contract with an established SME manufacturer in China:- "For continued exclusivity the contract provides for revenues of $1.4m and $10.2m in the Financial Years 2014-15 and 2015-16 respectively and the overall value of the contract over the next seven years is up to $159m, subject to the customer meeting its contractual revenue targets. Advanced cash payments totalling $260,000 are expected from the customer in the current Financial Year, part of which has already been received. The first supply commences in October 2014." Well let's just see if the referenced $10.2m comes through this year. Or indeed the $159million. What is the name of that Chinese manaufacturer? If you like having a laugh at other people, the biggest laugh is staring right back at you in the mirror. Foolish investing giants? It's easy to invest when it's someone else's money. One thing is quite clear Archway, you will never ever make it up the hill to Highgate. ALL IMO. DYOR. QP
archway1: Kromek's X-ray success IP-backed small cap's future looks bright Extensively used by hospitals ,Durham University spin-out Kromek aims to take x-ray technology into new markets using its own patent protected Cadmium Zinc Telluride (CZT) crystal technology. This is s high risk play that will not suit every investor but we believe that for those willing to roll the dice there is substantial growth here. Consensus share price targets are pitched north of 43p implying nearly 60% upside. The time looks right given the depressed share price and what we believe could be a major boardroom appointment coup. The £43 m ill company has signed up Sir Peter Williams as its non-executive chairman, a man who has successfully walked the tightrope between academia and commercial markets for decades, including as a UK goverment adviser on science and education policy and as a former chief executive officer (CEO) of Oxford Instruments the world class science and research kit and tools maker. The appointment implies sound council at the helm of this emerging business, with the political and corporate clout to help the company speed along its commercial sales execution. Kromek is identifying medical, security screening , homeland security and nuclear radiation detection markets with colour imaging equipment that is affordable , easy to use and that gives instant results.
quepassa: Perhaps one of the first tasks of the new Chairman may or may not be to consider finding a new Chief Executive to replace the current incumbent. In my opinion, the Company got off to a very bad start for failing almost immediately to deliver on the timing/delivery/pipeline of contracts which it had much spoken about at/during/before and after the IPO. It appears to me that this has dented ongoing credibility in the Company enormously. I personally find myself in a position of enthusiastically and urgently reaching for the salt cellar every time I read announcements by the Company. The share price performance since IPO speaks volumes and is wholly unacceptable in my opinion. ALL IMO> DYOR. QP
p1nkfish: lastly: 1) amphion mentioned expectations for kmk a week or 2 back - very positive. something going on only a 10%+ holder may have wind of? 2) share price rise convincingly since at volume. volume preceeds price. 3) all just prior to BoD meeting on July 1st. may just be a re-rating or is there something to be announced?

Kromek (KMK) Latest Trade

Kromek Most Recent Trade

Trade Type Trade Size Trade Price Trade Date Trade Time Currency
O 10,220 30.08 27 May 2016 14:29:58 GBX
Kromek share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20160528 16:01:30